1. Quantitative and qualitative effects of m-AMSA (amsacrine) on cellular immune components;Miller;Eur J Cancer Clin Oncol,1984
2. Phase I clinical and pharmacological study of 4′-(9-acridinylamino) methanesulfon-m-anisidide using an intermittent biweekly schedule;Van Echo;Cancer Res,1979
3. Phase I study of methanesulfonamide, N-(4-(9-acridinylamino-3-methoxyphenyl) (m-AMSA) using a single-dose schedule;Von Hoff;Cancer Treat Rep,1978
4. Phase I clinical investigation of 4′-(9-acridinylamino(methanesulfon-m-anisidine (NSC 249992), a new acridine derivative;Legha;Cancer Res,1978
5. Phase I study of m-AMSA in patients with solid tumors and leukemia;Goldsmith;Cancer Clin Trials,1980